- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04483466
Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH)
Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH): A Phase III Randomized Controlled Clinical Trial of the Efficacy of Methotrexate Monotherapy in the Treatment of Chronic Arthritis After Chikungunya Infection
Study Overview
Status
Intervention / Treatment
Detailed Description
- In the treatment group, participants will receive methotrexate 15mg by mouth/week with optional for increase up to 20mg/week in non-responders and folic acid 1mg by mouth daily for six months in Phase I.
- In the control group, participants will receive placebo methotrexate tablets by mouth/week with faux increase optional in non-responders and folic acid 1mg by mouth daily for six months in Phase I.
- In Phase II, patients may elect to stop taking the study drug or in those without clinical remission transition to open label active treatment group for the following six months.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Aileen Chang, MD, MSPH
- Phone Number: 202-677-6562
- Email: chang@email.gwu.edu
Study Contact Backup
- Name: Carlos Herrera, MD
- Phone Number: 202-677-6562
- Email: cherreragom41@email.gwu.edu
Study Locations
-
-
-
Barranquilla, Colombia
- Clinica de la Costa
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provision of signed and dated informed consent form.
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Male or female, aged >18 years
- Ability to take oral medication and be willing to adhere to the methotrexate regimen
- For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 3 months after the end of methotrexate administration.
- For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner.
- Have a diagnosis of CHIKV by CHIKV IgM or IgG antibody.
- The disease duration should be greater than 3 months (based on onset of symptoms).
- Screen laboratory tests must meet the following criteria: Hemoglobin ≥ 9 g/dL, WBCs ≥ 3.5 x 109 cells/L, Neutrophils ≥ 1.5 x 109 cells/L, Platelets ≥ 100 x 109 cells/L, serum transaminase levels not exceeding 1.5 times the upper limit of normal, serum creatinine ≤ 1.6 mg/dL, and negative for hepatitis B surface antigen and hepatitis C antibodies.
- Have a chest radiograph at screening that shows no clear evidence of malignancy or active infection.
- Have active moderate arthritis defined as at least 4 tender joints and at least one joint with definite clinical synovitis (swelling). Joints that may be considered in the count include the temporomandibular joints (0-2), sternoclavicular joints (0-2), acromioclavicular joints (0-2), glenohumeral joints (0-2), elbows (0-2), wrists (0-2), metacarpal phalangeal joints (0-10), finger proximal interphalangeal joints (0-10), finger distal interphalangeal joints (0-8), hips (0-2), knees (0-2), ankles (0-2), tarsus/midfoot (0-2), metatarsal phalangeal joints (0-10), toe proximal interphalangeal joints (0-10).
- Status-post complete Covid vaccination defined as at least 2 weeks after complete vaccination series.
Exclusion Criteria:
- Pregnancy or lactation
- Known allergic reactions to components of methotrexate or folic acid.
- Treatment with another investigational drug or other intervention within 1 month.
- History of chronic infection such as hepatitis and HIV. Patients with acute infection will have enrollment deferred until the infection resolves.
- Current signs or symptoms of uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic or cerebral disease.
- Patients with a current diagnosis of class III or IV CHF.
- History of lymphoproliferative disease including lymphoma.
- Overt or laboratory evidence of immunodeficiency syndromes.
- Any opportunistic infections, including but not limited to evidence of active cytomegalovirus, active Pneumocystis carinii, aspergillosis, histoplasmosis or atypical mycobacterium infection, within the previous 6 months at screening visit.
- History of substance abuse (drug or alcohol) within the previous 2 years.
- Intra-articular, soft tissue or intra-muscular corticosteroid injection during the 4 weeks prior to screening.
- History of prior use of methotrexate or biologic therapy.
- Evidence of active infection with fever >38°
- Current use of any other disease modifying arthritis medication including but not limited to sulfasalazine, methotrexate, hydroxychloroquine, leflunomide, or biologics in the previous 2 months. Patients on stable doses of prednisone up to 10 mg per day for at least 4 weeks prior to enrollment may participate. Non-steroidal anti-inflammatories (NSAIDS) and acetaminophen are permitted for pain during the study.
- Hematuria or proteinuria on urinalysis.
- The presence of anti-cyclic citrullinated peptide (Anti-CCP) antibodies >2 times the upper limit of normal.
- For patients who participate in synovial biopsy substudy the following additional exclusion criteria apply:
1. Known prior reactions or allergies to local anesthetics or antibiotics (specifically bupivocaine, lidocaine, or cephalexin) 2. Preexisting advanced structural or functional damage to joint of interest such as prior history of trauma requiring orthopedic surgery and hardware placement, and presence of prosthetic devices (artificial joints, pacemakers, other implantable devices) 3. History of diabetes, skin infections (cellulitis), bleeding disorders, deep vein thrombosis, pulmonary embolism, history or active cancer of any kind 4. Use of blood thinners (anticoagulants) 5. History of or current chronic pain syndrome such as fibromyalgia, chronic back pain, migraines, and history of current complex regional pain syndrome, and /or current or past chronic opiate treatment 6. Significant other comorbidities and /or medication use which in physician's clinical judgment may pause procedure or post-procedure complication risk.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment with methotrexate
100 participants will be treated with methotrexate
|
Methotrexate is vibrant yellow-orange colored powder with physical properties of near insolubility in water formulated into methotrexate tablets containing an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, and yellow.
The chemical name is N-[4-[[(2,4-diamino-6pteridinyl)methyl]methyl amino]benzoyl]-L-glutamic acid.
Methotrexate is an anti-metabolite that is a folate antagonist that inhibits lymphocyte proliferation and functions as an immunosuppressant in arthritis.
|
Placebo Comparator: Placebo methotrexate
50 will receive placebo
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of oral methotrexate treatment versus placebo for 6 months in chronic CHIKV arthritis.
Time Frame: up to 6 months
|
An improvement in the Disease Activity Score-28 response.
The DAS-28 is a composite measure including a tender and swollen joint joint of 28 joints, patient reported disease severity measures, and the c-reactive protein
|
up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Inflammation in the synovial tissue measured by synovial inflammatory cell infiltration
Time Frame: Up to 6 weeks
|
The investigators hypothesize that treatment with methotrexate versus placebo will decrease synovial macrophage and T-cell accumulation.
|
Up to 6 weeks
|
Inflammatory cytokine levels in synovial tissue
Time Frame: Up to 6 weeks
|
The investigators hypothesize that treatment with methotrexate versus placebo will dampen production of pathogenic cytokines like with TNF, IL-6, and MCP-1
|
Up to 6 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Joint Diseases
- Musculoskeletal Diseases
- Arbovirus Infections
- Vector Borne Diseases
- Alphavirus Infections
- Togaviridae Infections
- Arthritis
- Chikungunya Fever
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Methotrexate
Other Study ID Numbers
- Chang_MARCH_JUNE2020
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Investigate the Effect(s) of Methotrexate Treatment on Arthritis Disease Severity
-
Elina BrinckNot yet recruitingThe Effect of S-ketamine on Pharmacokinetics of Morphine, Hydromorphone, and Buprenorphine
-
University of CopenhagenArla Foods; Hoeng Fonden; Bionor PharmaUnknownTo Investigate the Effect of UHT Treated Milk Versus Pasteurised Milk on Bloodlipid ProfilDenmark
-
Cairo UniversityUnknownInvestigate the Renal Effect of DAAs on Egyption Patients After Completion of TreatmentEgypt
-
Peking University People's HospitalUnknownTo Investigate the Effect of Diclofenac on Pain Control of Knee Osteoarthritis and the Relationship Between Pain Relief and Medicine AdherenceChina
-
Medical University of ViennaRecruitingTo Investigate the Effect of 100% Oxygen Breathing on Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) in Healthy SubjectsAustria
-
Knoxville Orthopedic ClinicUnknownThe Primary Disease Process Being Studied is Shoulder OA and the Effect of an All Polyethelene Glenoid Component on Shoulder ArthroplastyUnited States
-
Heba A YassaEnrolling by invitationthe Study Focus on the Uses of Telephone and Other New Technology in Medicine, Diagnosis and TreatmentEgypt
-
Health NavigatorVastra Gotaland Region; Region Stockholm; Ostergotland County Council, Sweden; Uppsala... and other collaboratorsUnknownThe Focus is to Investigate Effect of a Case Management Interventions in Frequent Visitors to Emergency DepartmentsSweden
-
AstraZenecaCompletedThe Aim of This Study is to Investigate the Frequency and Related Risk Factors of Recurrence, and Quality of Life in Patients With GERD After Treatment With PPIKorea, Republic of
-
Guangxi Medical UniversityGuilin Medical College; Second Affiliated Hospital of Guangzhou Medical University and other collaboratorsUnknownTo Investigate the Characteristics and Prognostic Factors of T. Marneffei Infections and the Causes of Misdiagnosis | To Study the Recurrence Indicators and Establish a Therapeutic Effect Evaluation System of T. Marneffei InfectionsChina
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States